Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

Summary

This phase II trial studies how well poziotinib works in treating patients with non-small lung cancer with an EGFR or HER2 exon 20 mutation that is stage IV or has come back (recurrent). Poziotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth..

Timeline

Start

2017-03-17

Primary completion

2026-02-16

Completion

2026-02-16

Publications

• Miyamura BV, Mambetsariev I, Fricke J, Arias-Romero J, Cadman K, Shrestha S, Pisick E, Nguyen D, Malhotra J, Reyes A, Salgia R. Current paradigm of EGFRins20 in non-small cell lung cancer: A long way forward. Med. 2025 Sep 12;6(9):100803. doi: 10.1016/j.medj.2025.100803. Epub 2025 Aug 8.
• Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G Jr, Tsao AS, Heymach JV. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell. 2022 Jul 11;40(7):754-767.e6. doi: 10.1016/j.ccell.2022.06.006.
• Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G Jr, Tsao AS, Heymach JV. Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol. 2022 Mar 1;40(7):702-709. doi: 10.1200/JCO.21.01113. Epub 2021 Sep 22.

Drugs

Indications